Evidence map›Paper›PMID 20592859›Full record

ReviewOrganogenesis

Microvascular rarefaction: the decline and fall of blood vessels.

Michael S Goligorsky

Open access · bronzeAbstract readReview
In one paragraph

Review in Organogenesis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Molecular Mechanisms Governing Vascular Function in Heart Failure.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. The Implications of Aging on Vascular Health.International journal of molecular sciences · 2024
    Review
  17. Observational
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Michael S GoligorskyDepartments of Medicine, Pharmacology and Physiology, Renal Research Institute, New York Medical College, Valhalla, NY, USA. michael_goligorsky@nymc.edu
New York Medical College · US

Funding

Washington University Center for Kidney Disease ResearchP30DK079333 · NIDDK · WASHINGTON UNIVERSITY · PI HAMMERMAN, MARC RANDALL · 2007 to 2011
$5.1M
RENAL ENDOTHELIAL AND SMOOTH MUSCLE CELLS INTERACTIONSR01DK045462 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI GOLIGORSKY, MICHAEL S · 1995 to 2014
$4.8M
VASCULAR PERMEABILITY IN DIABETIC NEPHROPATHYR01DK054602 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI GOLIGORSKY, MICHAEL S · 1999 to 2010
$2.5M
Endothelial dysfunction in acute renal ischemiaR01DK052783 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI GOLIGORSKY, MICHAEL S · 1997 to 2007
$2.0M
NIDDK NIH HHS DK052783NIDDK NIH HHS DK079333NIDDK NIH HHS DK45462NIDDK NIH HHS DK54602NIDDK NIH HHS P30 DK079333NIDDK NIH HHS R01 DK045462NIDDK NIH HHS R01 DK052783NIDDK NIH HHS R01 DK054602
6 · The paper itself

Abstract

The goals of this presentation are two-fold: (1) to briefly sketch the field of vascular rarefaction as a key component of various fibrotic diseases and (2) to illustrate it with four vignettes depicting diverse mechanisms of microvascular rarefaction. Specifically, I shall describe migratory and angiogenic incompetence of endothelial cells under conditions of reduced bioavailability of nitric oxide, role of endothelial-to-mesenchymal cell and mesenchymal stem cell-to-endothelial reprogramming, and potential role of antiangiogenic peptides in the development of graft vascular disease as exemplified by chronic allograft nephropathy.

Indexed as

AnimalsEndothelial CellsHumansMicrovesselsVascular Diseasescell reprogrammingendorepellinendostatinendothelial cell dysfunctionendothelial cell migrationendothelial-mesenchymal transition

Identifiers

PMID20592859
PMCPMC2861737
OpenAlexW2030611819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.